PCV74 COST-EFFECTIVENESS OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.799
https://www.valueinhealthjournal.com/article/S1098-3015(19)33177-8/fulltext
Section Title :
Section Order :
10700
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33177-8&doi=10.1016/j.jval.2019.09.799